Alnylam Pharmaceuticals is seeking an Associate Director to lead downstream development for emerging modalities, with emphasis on antibody purification and Antibody Oligo Conjugate purification. You will guide CMC strategy and partner with CDMOs to advance programs from preclinical to Phase I.
You will design scalable purification processes, define control strategies, and contribute to regulatory submissions while coordinating with cross-functional teams across research, analytical development,
#J-18808-LjbffrDownstream CMC Lead for Emerging Modalities in cambridge at Unknown Company
This position is listed as full time and onsite.